Cushing's Syndrome in France: Symptoms, Causes & Treatment | aihealz
EndocrinologymoderateICD-10 · E24.9
Cushing's Syndrome.Care & specialists in France
In France, cushing's Syndrome is managed by endocrinologists. Cushing's syndrome is the constellation of physical and metabolic changes that result from chronic exposure to excess glucocorticoids, most often from prescribed corticosteroid medication and less commonly from endogenous overproduction of cortisol. Iatrogenic Cushing's is common — anyone on supraphysiologic prednisone, dexamethasone, or potent inhaled or topical steroids for more than a few weeks can develop the syndrome — while endogenous Cushing's is rare, with an incidence of 0.7-2.4 cases per million per year.
aliases · Cushing's syndrome (cortisol excess)· Hypercortisolism· Cushing's disease· Síndrome de Cushing· reviewed May 14, 2026
EB
Reviewed by AIHealz Medical Editorial Board · EndocrinologyLast reviewed May 13, 2026
Cushing's syndrome (ICD-10: E24) is a clinical disorder caused by chronic exposure to excess glucocorticoid. Aetiologically it is divided into exogenous (iatrogenic) Cushing's, from administration of glucocorticoid medication, and endogenous Cushing's, from unregulated production of cortisol by the adrenal cortex. Endogenous Cushing's is further divided by ACTH dependence: ACTH-dependent forms (around 80%) include Cushing's disease (a pituitary corticotroph adenoma releasing ACTH, around 70% of endogenous cases) and ectopic ACTH syndrome (most often from small-cell lung carcinoma, bronchial or thymic carcinoid, medullary thyroid carcinoma, or pancreatic neuroendocrine tumor); ACTH-independent forms (around 20%) include unilateral cortisol-secreting adrenal adenoma, adrenal carcinoma, primary bilateral macronodular adrenal hyperplasia, and primary pigmented nodular adrenal disease. Cushing's disease is the name given specifically to the pituitary form, originally described by Harvey Cushing in 1932; Cushing's syndrome is the broader clinical phenotype regardless of cause.
key facts
Prevalence
Endogenous Cushing's: incidence 0.7-2.4 per million per year; prevalence approximately 39-79 per million. Iatrogenic Cushing's: orders of magnitude more common, affecting up to 1% of long-term oral glucocorticoid users
Demographics
Endogenous Cushing's affects women 3-5 times more than men; peak age 25-50
Avg. age
Cushing's disease (pituitary) peaks in the third to fifth decade; ectopic ACTH typically in older adults with lung tumors
Global cases
Estimated several hundred thousand patients with endogenous Cushing's globally; tens of millions exposed to long-term systemic glucocorticoids
Specialist
Endocrinology
ICD-10
E24.9
§ 02
How you might notice it
The key symptoms of Cushing's Syndrome are: Progressive central obesity with truncal weight gain, supraclavicular and dorsocervical fat pads (the so-called moon face and buffalo hump), and relatively thin arms and legs from proximal muscle wasting., New or rapidly worsening violaceous abdominal, axillary, and thigh striae more than 1 cm wide — a highly specific sign reflecting collagen loss in the dermis., Easy bruising after minor trauma, thin atrophic skin that tears with adhesive removal, and poor wound healing., Hypertension with diastolic predominance, frequently resistant to standard antihypertensives., New or markedly worsening type 2 diabetes or impaired glucose tolerance from cortisol-driven gluconeogenesis and insulin resistance., Proximal muscle weakness — difficulty rising from a chair, climbing stairs, or lifting arms above the head — that often precedes other features by months., Hirsutism, acne, oligomenorrhoea or amenorrhoea, and androgenic alopecia in women, particularly in adrenal carcinoma where androgen excess is prominent..
01Progressive central obesity with truncal weight gain, supraclavicular and dorsocervical fat pads (the so-called moon face and buffalo hump), and relatively thin arms and legs from proximal muscle wasting.
02New or rapidly worsening violaceous abdominal, axillary, and thigh striae more than 1 cm wide — a highly specific sign reflecting collagen loss in the dermis.
03Easy bruising after minor trauma, thin atrophic skin that tears with adhesive removal, and poor wound healing.
04Hypertension with diastolic predominance, frequently resistant to standard antihypertensives.
§ 03
How it’s diagnosed
diagnosis
Diagnosis proceeds in three steps: confirm hypercortisolism, determine whether it is ACTH-dependent or independent, and localize the source. The first step is recognition — clinicians should screen any patient with multiple features, particularly violaceous striae, proximal myopathy, easy bruising, supraclavicular fat pads, or resistant hypertension and diabetes appearing together. Screening tests recommended by the Endocrine Society are: 24-hour urinary free cortisol (collected over 2-3 separate days), late-night salivary cortisol (collected at 23:00 on two separate evenings; ideally a normal cortisol nadir is below 4 nmol/L or 1.5 ng/mL), and the overnight 1 mg dexamethasone suppression test (suppression of plasma cortisol to under 50 nmol/L or 1.8 µg/dL excludes Cushing's). Two positive screening tests confirm hypercortisolism. Once hypercortisolism is confirmed, plasma ACTH separates ACTH-dependent (ACTH >15 pg/mL) from ACTH-independent (ACTH <5 pg/mL) disease. In ACTH-dependent cases, MRI of the pituitary, high-dose dexamethasone suppression, and inferior petrosal sinus sampling (IPSS) distinguish Cushing's disease from ectopic ACTH syndrome — IPSS achieves over 95% accuracy in experienced centres. CRH stimulation and desmopressin testing are sometimes used. In ACTH-independent disease, CT or MRI of the adrenals localizes the lesion. For ectopic disease, 68Ga-DOTATATE PET-CT, octreoscan, and chest-abdomen CT search for occult neuroendocrine tumors. Pseudo-Cushing states require dexamethasone-CRH testing or repeated late-night salivary cortisol once the suspected trigger (alcohol, depression, severe stress) is controlled.
Key tests
01
Late-night salivary cortisolDetects loss of normal evening cortisol nadir — a sensitive screen for hypercortisolism
02
24-hour urinary free cortisol (×2-3 collections)Quantifies integrated cortisol production over 24 hours
Transsphenoidal endoscopic pituitary surgeryCure rates 65-90% for microadenomas and 50-70% for macroadenomas; recurrence rate 10-25% over 10 years
Laparoscopic adrenalectomyCure rate over 95% for benign adenoma; contralateral adrenal function typically recovers within 6-18 months
Open adrenalectomy for adrenocortical carcinoma5-year overall survival 40-55% for localized resectable disease; under 20% for metastatic disease
Bilateral adrenalectomyImmediate biochemical control in over 95%; trade-off is lifelong adrenal insufficiency
§ 05
Causes & risk factors
known causes
Exogenous glucocorticoid administration
Oral prednisone or dexamethasone, intra-articular and epidural injections, potent topical or inhaled steroids over prolonged periods, or megestrol acetate (which has glucocorticoid activity) can all produce iatrogenic Cushing's. By far the most common cause globally and the first to exclude in every patient.
A monoclonal adenoma of pituitary corticotrope cells autonomously secretes ACTH, driving bilateral adrenal hyperplasia and cortisol excess. Usually a microadenoma (under 6 mm) and challenging to identify on MRI in roughly 40% of cases. USP8 somatic mutations are present in about a third of adenomas.
Ectopic ACTH secretion by non-pituitary tumor
Small-cell lung carcinoma is the classic cause, but slow-growing neuroendocrine tumors — bronchial carcinoid, thymic carcinoid, pancreatic neuroendocrine tumor, medullary thyroid carcinoma, and pheochromocytoma — can also secrete ACTH. Slow-growing tumors mimic Cushing's disease clinically and biochemically; rapid-growing tumors produce severe acute hypercortisolism with profound hypokalemia.
Cortisol-secreting adrenal adenoma or carcinoma
Unilateral adrenal tumor produces cortisol independently of ACTH. Adenomas are usually well-defined and benign on imaging; adrenal carcinoma is larger, heterogeneous, and may co-secrete androgens producing virilization. Plasma ACTH is suppressed and the contralateral adrenal is atrophic.
Primary bilateral macronodular or pigmented nodular adrenal disease
Bilateral adrenal hyperplasia or multiple cortisol-producing nodules that function autonomously. Macronodular forms can be familial (ARMC5 mutations) and may have aberrant expression of GIP, vasopressin, or beta-adrenergic receptors. Primary pigmented nodular adrenocortical disease is part of Carney complex (PRKAR1A mutations).
Pseudo-Cushing states (functional hypercortisolism)
§ 06
Living with it
01Use the lowest effective dose of glucocorticoid for the shortest necessary time; review chronic prescriptions every 3-6 months.
02Prefer topical, inhaled, or local injection routes when systemic therapy can be avoided.
03Avoid concomitant use of CYP3A4 inhibitors (ritonavir, itraconazole) with potent inhaled steroids, which can cause iatrogenic Cushing's.
04Screen adrenal incidentalomas larger than 1 cm for autonomous cortisol secretion at diagnosis.
05Educate patients on chronic glucocorticoids about adrenal insufficiency risk and provide a steroid card or medical-alert bracelet.
06Schedule regular bone-density assessment and vitamin D / calcium repletion in any patient on glucocorticoids longer than 3 months.
recommended foods
•High-protein diet (1.2-1.5 g/kg/day) to counter muscle wasting
•Calcium- and vitamin-D-rich foods (dairy or fortified alternatives) to protect bone
§ 07
When to seek help
why see an endocrinology
Cushing's diagnosis and management are highly subspecialty-dependent. An endocrinologist with experience in pituitary and adrenal disease coordinates testing, interprets discordant results, and selects between medical and surgical options. Pituitary or adrenal surgery should be performed by high-volume surgeons because outcomes correlate strongly with operative volume.
01Cardiovascular disease — accelerated atherosclerosis, hypertension, dyslipidemia, and arrhythmia; persistent cardiovascular risk even after cure.
02Venous thromboembolism — 3-10× increased risk; routine pharmacological prophylaxis around surgery is standard.
03Type 2 diabetes mellitus and impaired glucose tolerance; often improves with cortisol control but persists in roughly 30%.
04Osteoporosis and low-trauma fractures — universal in active disease; bone-density recovery is slow and incomplete.
05Opportunistic infections (Pneumocystis, candida, herpes zoster, atypical mycobacteria) during active hypercortisolism.
06Psychiatric morbidity — depression, anxiety, cognitive impairment, occasional psychosis; long-term impact on quality of life is the most underappreciated complication.
Iatrogenic (exogenous) Cushing's syndromeCaused by exogenous glucocorticoid administration — oral prednisone or dexamethasone, intra-articular or epidural injections, potent topical steroids over large body-surface area, or inhaled high-dose corticosteroids. By far the most common form globally. Reversible on cautious dose reduction.
Cushing's disease (pituitary ACTH-secreting adenoma)Approximately 70% of endogenous cases. A pituitary corticotroph adenoma — usually a microadenoma under 6 mm — autonomously secretes ACTH, driving bilateral adrenal hyperplasia and cortisol excess. Women affected 3-5 times more often than men.
Ectopic ACTH syndromeRoughly 10-15% of endogenous Cushing's. Non-pituitary neoplasms (small-cell lung carcinoma, bronchial or thymic carcinoid, pancreatic neuroendocrine tumor, medullary thyroid cancer, pheochromocytoma) secrete ACTH or CRH ectopically. Aggressive presentation with rapid onset, severe hypokalemia, hyperpigmentation, and weight loss in some cancers.
Adrenal Cushing's (cortisol-secreting adrenal tumor)Roughly 15-20% of endogenous cases. Unilateral cortisol-producing adrenal adenoma (most common), adrenocortical carcinoma (aggressive, often with androgen excess), or bilateral macronodular or micronodular hyperplasia. ACTH is suppressed and the contralateral adrenal is atrophic.
Cyclical Cushing's syndromeEpisodic cortisol hypersecretion with intervals of normal or even subnormal cortisol; can arise from any of the above causes. Diagnosis requires repeated testing during symptomatic phases and a high index of suspicion.
Subclinical (mild autonomous cortisol secretion)Found in roughly 10-15% of adrenal incidentalomas. Cortisol secretion is mildly autonomous without overt clinical features; nonetheless associated with increased cardiovascular events, diabetes, osteoporosis, and mortality.
Living with Cushing's Syndrome
Timeline
Weeks 1-4: cortisol control after surgery or with osilodrostat/metyrapone; adrenal insufficiency requires hydrocortisone cover. Months 1-6: blood pressure, glucose, and electrolytes normalize; muscle strength begins to return. Months 6-12: weight redistributes from central to peripheral; striae fade from violaceous to pale; menstrual cycles resume. Years 1-3: bone density recovers slowly; cognitive and mood symptoms improve. HPA axis recovers in roughly 70% of patients by 24 months after surgical cure.
Lifestyle
01Adhere strictly to prescribed medical therapy and attend cortisol monitoring appointments.
02Carry an emergency steroid kit and identification once on replacement therapy.
04Track weight, blood pressure, and home glucose closely during active disease.
05Reduce salt intake to manage volume overload and hypertension.
06Engage in resistance training under physiotherapy supervision to counter steroid-induced myopathy.
Daily management
01Take cortisol-lowering medications at fixed times to maintain steady levels.
02
Complementary approaches
Pituitary radiotherapy (stereotactic radiosurgery or fractionated radiotherapy)Indicated for residual or recurrent Cushing's disease after surgery, or as primary treatment when surgery is contraindicated. Stereotactic radiosurgery (gamma knife) is single-session; fractionated radiotherapy is delivered over 4-6 weeks. Onset of cortisol control takes 12-36 months.
Choosing a doctor
Choose an endocrinologist affiliated with a designated pituitary or neuroendocrine centre, ideally with access to inferior petrosal sinus sampling, dynamic pituitary MRI, and the full range of medical therapies. For pituitary surgery, look for a neurosurgeon performing at least 50 transsphenoidal cases per year and reporting cure rates with hormone-specific follow-up data.
Pituitary Network Association →US-based patient organisation covering pituitary tumors including Cushing's disease, with surgeon directories and patient guides.
Cushing's syndrome is the clinical condition caused by chronically high levels of the stress hormone cortisol. It can result from prescribed corticosteroid medication or from a tumor that overproduces cortisol or ACTH. Untreated, it causes weight gain, hypertension, diabetes, bone loss, mood change, and increased mortality.
What is the difference between Cushing's syndrome and Cushing's disease?▾▴
Cushing's syndrome is the broader clinical phenotype of cortisol excess from any cause. Cushing's disease is the specific subtype caused by an ACTH-secreting pituitary adenoma — Harvey Cushing's original 1932 description. About 70% of endogenous Cushing's syndrome is Cushing's disease.
What causes Cushing's syndrome?▾▴
By far the most common cause is prescribed glucocorticoid medication (iatrogenic Cushing's). Endogenous causes are rare and include pituitary adenomas (Cushing's disease, 70%), adrenal tumors (15-20%), and ectopic ACTH from lung or other neuroendocrine tumors (10-15%).
What are the first signs of Cushing's syndrome?▾▴
Early features include progressive central weight gain, new violaceous striae, easy bruising, proximal muscle weakness (difficulty climbing stairs), resistant hypertension, and new or worsening diabetes. Mood change and sleep disturbance often precede physical findings.
How is Cushing's syndrome diagnosed?▾▴
Diagnosis is a three-step process. First, hypercortisolism is confirmed with two of three tests: late-night salivary cortisol, 24-hour urinary free cortisol, or overnight 1 mg dexamethasone suppression. Plasma ACTH then divides cases into ACTH-dependent or independent. Pituitary or adrenal imaging and sometimes inferior petrosal sinus sampling localize the source.
Is Cushing's syndrome curable?▾▴
Yes, in most cases. Pituitary surgery cures 65-90% of Cushing's disease microadenomas; adrenal surgery cures over 95% of cortisol-producing adenomas. Iatrogenic Cushing's resolves with gradual glucocorticoid taper. Adrenocortical carcinoma and ectopic ACTH from malignant tumors have a more variable cure rate.
What is iatrogenic Cushing's syndrome?▾▴
Iatrogenic Cushing's is caused by exogenous glucocorticoid medication — oral prednisone or dexamethasone, joint or epidural steroid injections, potent topical or inhaled steroids — used in supraphysiologic doses for weeks to months. It is the most common form of Cushing's and reverses with slow steroid taper.
What is the main treatment for Cushing's disease?▾▴
First-line treatment is transsphenoidal pituitary surgery to remove the ACTH-secreting adenoma. Cure rates reach 90% for microadenomas in high-volume centres. When surgery fails or is contraindicated, second-line options include radiotherapy, medical therapy (osilodrostat, ketoconazole, pasireotide), and bilateral adrenalectomy.
How long does it take to recover from Cushing's syndrome?▾▴
Cortisol levels normalize within days to weeks after surgical or medical treatment. Physical features fade gradually: muscle strength returns within 3-6 months, striae fade from purple to pale over 12-18 months, and weight redistributes over a year. Bone density and cognitive function recover slowly over 1-3 years.
Can stress cause Cushing's syndrome?▾▴
Severe psychological stress, depression, and uncontrolled alcohol use can produce mild biochemical hypercortisolism known as pseudo-Cushing. It is reversible with treatment of the underlying problem and does not produce true catabolic features such as striae, proximal myopathy, or easy bruising.
Is Cushing's syndrome hereditary?▾▴
Most cases are sporadic, but several genetic syndromes predispose to endocrine tumors that can cause Cushing's, including multiple endocrine neoplasia type 1 (MEN1), Carney complex (PRKAR1A), and familial isolated pituitary adenoma (AIP). Familial macronodular adrenal hyperplasia is associated with ARMC5 mutations.
What is the survival rate of Cushing's syndrome?▾▴
Untreated endogenous Cushing's has 5-year mortality of 30-50%, mainly from cardiovascular disease, infection, and thromboembolism. With successful surgery or medical control of cortisol, mortality approaches that of the general population, although some residual cardiovascular risk persists.
Why does Cushing's syndrome cause moon face?▾▴
Chronic cortisol excess redistributes adipose tissue centrally, depositing fat in the face, supraclavicular fossae, and dorsocervical area while wasting subcutaneous fat from the limbs. The rounding of the facial contour is termed moon face and is a hallmark of established Cushing's.
Can children get Cushing's syndrome?▾▴
Yes, although it is rare. Pediatric Cushing's most often arises from pituitary microadenomas or adrenal adenomas; carcinoma is more common than in adults. Growth arrest combined with weight gain in a child is the most characteristic clue and should prompt cortisol testing.
How is inferior petrosal sinus sampling done?▾▴
Inferior petrosal sinus sampling (IPSS) is performed by an interventional radiologist who advances catheters through the groin veins into both petrosal sinuses below the pituitary. ACTH is measured at baseline and after CRH stimulation. A high central-to-peripheral ratio confirms a pituitary source with over 95% accuracy.
What is osilodrostat?▾▴
Osilodrostat is an oral medication approved in 2020 for Cushing's disease. It inhibits the 11β-hydroxylase enzyme in cortisol synthesis and produces rapid cortisol normalization in roughly 86% of patients at 24 weeks. The main side-effects are hypokalemia, hyperandrogenism, and QT prolongation.
Can Cushing's syndrome cause infertility?▾▴
Yes. Cortisol excess suppresses gonadotropin secretion, causing amenorrhea or oligomenorrhoea in 70-80% of women and erectile dysfunction in many men. Most reproductive function returns after biochemical control, but adrenal androgen excess from adrenal carcinoma can produce persistent hirsutism and virilization.
What is Nelson syndrome?▾▴
Nelson syndrome is the rapid growth of a pituitary corticotroph adenoma after bilateral adrenalectomy for Cushing's disease, occurring in roughly 20% of such patients. It produces increasing hyperpigmentation, headache, and visual loss. Pituitary irradiation around the time of adrenalectomy reduces the risk.
Can Cushing's syndrome be misdiagnosed?▾▴
Yes. The features overlap with very common conditions — obesity, type 2 diabetes, hypertension, PCOS, depression — and diagnosis is often delayed by 2-5 years. Repeated weight gain with hypertension and diabetes in a young adult, especially with striae or proximal weakness, warrants cortisol screening.
Do you need lifelong medication after Cushing's surgery?▾▴
Most patients require hydrocortisone replacement for months to years after successful surgery while the suppressed hypothalamic-pituitary-adrenal axis recovers. About 70% recover full function within 24 months and can stop replacement. After bilateral adrenalectomy or recurrent disease, replacement may be lifelong.
What follow-up is needed after Cushing's treatment?▾▴
Long-term follow-up includes annual or biannual late-night salivary cortisol and 24-hour urinary free cortisol to detect recurrence, monitoring of blood pressure, glucose, lipids, and bone density, and surveillance of pituitary or adrenal imaging. Cushing's disease can recur years after apparent cure.
05New or markedly worsening type 2 diabetes or impaired glucose tolerance from cortisol-driven gluconeogenesis and insulin resistance.
06Proximal muscle weakness — difficulty rising from a chair, climbing stairs, or lifting arms above the head — that often precedes other features by months.
07Hirsutism, acne, oligomenorrhoea or amenorrhoea, and androgenic alopecia in women, particularly in adrenal carcinoma where androgen excess is prominent.
08Mood disturbance — depression, anxiety, irritability, emotional lability, insomnia, and occasionally psychosis — present in up to 70% of patients.
09Recurrent skin and soft-tissue infections, dental caries, and reactivation of latent infections (TB, fungal disease) from immune suppression.
10Low-trauma vertebral or rib fractures and osteoporosis on DEXA, often the presenting complaint in older patients.
11Hyperpigmentation of skin folds, gums, and recent scars in ACTH-dependent disease — most prominent in ectopic ACTH syndrome.
12Polyuria, polydipsia, and weight loss with rapid onset and marked hypokalemia in ectopic ACTH-secreting malignancy.
early warning signs
•Difficulty losing weight despite calorie restriction and rising central waist circumference
•New violaceous striae in unusual locations (axillae, breasts, thighs) within months
•Resistant hypertension requiring three or more antihypertensives in a young adult
•Steroid-induced diabetes following corticosteroid administration
•Vertebral compression fracture in a premenopausal woman or middle-aged man without other risk factors
● emergency signs
•Acute psychosis, severe depression with suicidal ideation, or new manic episode in a patient on glucocorticoids or with suspected Cushing's
•Severe hypokalemia (potassium under 3.0 mmol/L) with metabolic alkalosis — classic for ectopic ACTH and severe Cushing's; risk of arrhythmia
•Adrenal crisis after surgical cure or abrupt cessation of long-term glucocorticoid therapy — hypotension, hypoglycemia, vomiting; requires immediate IV hydrocortisone
Overnight 1 mg dexamethasone suppression testScreens for loss of normal cortisol suppression in response to exogenous glucocorticoid
04
Plasma ACTH and high-dose (8 mg) dexamethasone suppression testDistinguishes ACTH-dependent from ACTH-independent Cushing's and helps separate pituitary from ectopic ACTH
05
Pituitary MRI with dynamic contrastIdentifies pituitary corticotroph adenoma; sensitivity around 60-70% even with optimal protocols
06
Inferior petrosal sinus sampling (IPSS) with CRH stimulationGold standard for distinguishing Cushing's disease from ectopic ACTH; can also lateralize the pituitary adenoma
07
CT or MRI of the adrenalsLocalizes cortisol-secreting adrenal adenoma, carcinoma, or bilateral hyperplasia in ACTH-independent disease
08
68Ga-DOTATATE PET-CTLocalizes occult ectopic ACTH-secreting neuroendocrine tumors when CT and MRI are negative
Outlook
Outlook is excellent with timely diagnosis and effective treatment, and dismal without it. Untreated endogenous Cushing's carries 5-year mortality of 30-50%, driven by cardiovascular events, thromboembolism, opportunistic infection, and metabolic complications. With surgical or medical control of cortisol, mortality falls and approaches that of the general population, although some excess cardiovascular risk persists for years. Pituitary surgery cures 65-90% of microadenomas and 50-70% of macroadenomas at first operation; recurrence develops in 10-25% over a decade and requires lifelong surveillance with late-night salivary cortisol and 24-hour urinary free cortisol. Adrenal adenoma is cured by laparoscopic adrenalectomy in over 95%. Adrenocortical carcinoma has a much poorer outlook, with 5-year overall survival of 40-55% for localized resectable disease and under 20% for metastatic disease. Reversal of physical features after successful treatment is substantial — striae fade and muscle bulk returns within 6-18 months — but bone loss recovers slowly and cognitive and mood symptoms may take 1-3 years to improve. Up to 50% of patients have persistent quality-of-life impairment after biochemical cure, justifying long-term multidisciplinary follow-up.
Severe alcohol use, depression, anxiety disorders, severe obesity, polycystic ovary syndrome, uncontrolled diabetes, and pregnancy can produce mild biochemical hypercortisolism that mimics Cushing's. Important to identify before invasive testing or surgery.
risk factors
Long-term systemic or high-potency topical glucocorticoid usemodifiable
Risk is dose- and duration-dependent. Prednisone equivalents of 7.5 mg/day or more for several months, repeated joint or epidural injections, and potent topical steroids over large body-surface area are common triggers. Inhaled steroids at high dose (especially in HIV patients on ritonavir-based regimens) can produce systemic Cushing's.
Female sex (endogenous)non-modifiable
Endogenous Cushing's is 3-5 times more common in women, especially Cushing's disease and adrenal adenoma; ectopic ACTH is more often male.
Age 25-50 years (Cushing's disease)non-modifiable
Cushing's disease most often presents in the third to fifth decade; ectopic ACTH and adrenal carcinoma can present at any age.
Pre-existing pituitary or adrenal lesionnon-modifiable
Patients with incidentally discovered adrenal adenomas or pituitary microadenomas have a higher prevalence of subclinical and overt Cushing's; screening of incidentalomas is now standard.
Genetic syndromesgenetic
Multiple endocrine neoplasia type 1 (MEN1), Carney complex (PRKAR1A), familial isolated pituitary adenoma (AIP), McCune-Albright syndrome (GNAS), and ARMC5 mutations all predispose to Cushing's.
Underlying neuroendocrine tumornon-modifiable
Bronchial, thymic, and pancreatic neuroendocrine tumors and medullary thyroid carcinoma can secrete ACTH ectopically.
•
Potassium-rich foods (bananas, oranges, leafy greens) in patients on ketoconazole or osilodrostat with hypokalemia
•Mediterranean-pattern diet to address coexisting diabetes and dyslipidemia
foods to avoid
•Excess salt and processed foods that worsen hypertension and edema
•Refined carbohydrates and sugary drinks that worsen steroid-induced hyperglycemia
•Excessive alcohol that contributes to bone loss and hepatotoxicity (relevant on ketoconazole)
•Grapefruit juice if taking ketoconazole or osilodrostat — CYP3A4 interaction
07Adrenal insufficiency or crisis after surgical cure or rapid taper; lifelong steroid-card and education essential.
08Nelson syndrome (corticotroph adenoma expansion with hyperpigmentation and pituitary enlargement) after bilateral adrenalectomy in roughly 20%.
choosing the right hospital
01Endocrinology service with experience in Cushing's diagnostic algorithms
02Pituitary-dedicated neurosurgical team performing >50 transsphenoidal cases/year
03Interventional radiology team experienced in inferior petrosal sinus sampling
04Laparoscopic adrenal surgery service and high-volume oncology service for adrenocortical carcinoma
05Stereotactic radiosurgery and fractionated radiotherapy availability
Essential facilities
Designated pituitary and neuroendocrine tumor centresTertiary endocrinology departments with cortisol and ACTH assay reliabilityInterventional radiology suites for IPSSAdrenal surgery services within urology or general surgeryPituitary-radiotherapy and stereotactic-radiosurgery units
Compare →
Self-monitor blood pressure and home glucose if abnormalities are present.
03Track weight weekly during active treatment and after surgery to detect adrenal insufficiency.
04Apply broad-spectrum sun protection because thin steroid-affected skin burns easily.
05Attend periodic ophthalmology follow-up if pituitary surgery has affected vision.
06Carry emergency hydrocortisone after pituitary or adrenal surgery for sick-day use.
Exercise
Resistance training under physiotherapy supervision (twice weekly) is the most effective intervention against proximal myopathy. Low-impact aerobic activity (walking, swimming) protects against deconditioning. Avoid high-impact loading during severe osteoporosis; falls prevention is essential.